Posted by Michael Wonder on 02 May 2022
U.S. FDA declines to approve two more China tested drugs
2 May 2022 - The U.S. FDA declined to approve two China tested cancer treatments on Monday, raising concerns over the future of drugs tested in single-country trials.
The decisions could add pressure on Chinese stocks, especially biotech companies, at a time shares of several U.S. listed Chinese companies have been falling on the potential risk of being delisted.
